Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
New Programs to Build on Our Market Leadership Position in Uncontrolled Gout
Next-Generation Uncontrolled Gout Programs
Potential to improve response rate and duration of treatment, and provide more
convenient administration through subcutaneous dosing
Novel Gout
Discovery Program
HZN-003
Optimized uricase and optimized
PEGylation for uncontrolled gout
Potency allowing potential for
subcutaneous dosing
HZN-007(1)
Optimized uricase and PASylation
for uncontrolled gout
PASylation as a new approach to
increasing half-life and reducing
immunogenicity
Potency allowing potential for
subcutaneous dosing
•
(1) Being developed under a collaboration agreement with XL Protein GmbH.
HI HORIZON
HemoShear Collaboration
Strong capability to identify and
validate novel biological targets
Exploring novel approaches
to treating gout
33View entire presentation